NCT02004275|UnknownPhase 1ResultsDMC

Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy

Alliance for Clinical Trials in Oncology ClinicalTrials.gov

Compare

3 other identifiers

A061202NCI-2013-01702U10CA031946

Study Type

interventional

Target

118

Locations

1 country

Sites

336

Timeline

RegisteredDec 2013

StartedFeb 2014

Brief Summary

This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to see how well pomalidomide and dexamethasone with or without ixazomib works in treating patients with multiple myeloma that has come back. Biological therapies, such as pomalidomide and dexamethasone, may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pomalidomide and dexamethasone are more effective with or without ixazomib in treating multiple myeloma.

Trial Health

Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

118

participants targeted

Target at P75+ for phase_1

Geographic Reach

1 country

336 active sites

Status

unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 26, 2013

Completed

13 days until next milestone

First Posted

Study publicly available on registry

December 9, 2013

Completed

2 months until next milestone

Study Start

First participant enrolled

February 1, 2014

Completed

7.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed

2 years until next milestone

Results Posted

Study results publicly available

December 1, 2023

Completed

Last Updated

December 1, 2023

Status Verified

November 1, 2023

Enrollment Period

7.8 years

First QC Date

November 26, 2013

Results QC Date

January 11, 2023

Last Update Submit

November 9, 2023

Conditions

Multiple Myeloma in Relapse

Outcome Measures

Primary Outcomes (2)

Maximum Tolerated Dose (MTD) of Pomalidomide and Ixazomib, Determined According to Incidence of Dose Limiting Toxicity (DLT) Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (Phase I)
For this protocol, dose-limiting toxicity (DLT) will be defined by the following adverse events at least possibly related to study therapy: Grade 3 or higher non-hematologic toxicity, with the following exceptions: Alopecia is not expected but would not be considered a DLT. Nausea, vomiting and diarrhea will only be considered a DLT if it cannot be adequately managed with optimal supportive care. Grade 3 or 4 hyperglycemia due to dexamethasone will only be considered a DLT if it cannot be controlled with appropriate therapy Grade 4 hematologic toxicity, with the following exceptions: Grade 4 lymphopenia is expected with this regimen and will not be construed as a DLT. Grade 4 neutropenia will only be considered a DLT if it lasts longer than 7 days despite appropriate supportive care. Grade 4 thrombocytopenia will only be considered a DLT if it lasts longer than 7 days or is associated with greater then or equal to grade 3 bleeding event
28 days
Progression Free Survival (PFS) (Phase II)
progression-free survival (PFS), defined as the time from randomization to the date the International Myeloma Working Group (IMWG) criteria for disease progression is met. If a patient initiates another anti-cancer treatment prior to disease progression, they will be censored at the date of initiation of this treatment. Patients will be randomized to treatment using the Pocock-Simon algorithm balancing the distribution of the following stratification factors between the two treatment arms: 1) ISS 1-2 disease vs. ISS 3 disease (current ISS stage based off screening beta 2 microglobulin and albumin) 2) High risk cytogenetics features: yes vs. no High risk cytogenetics features include: del(1p), gain of 1q, t(4;14), t(14;16), t(14; 20), del(17p) 3) Prior treatment with a proteasome inhibitor: yes vs. no
3 years

Secondary Outcomes (12)

Incidence and Type of Dose Limiting Toxicities (DLTs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (Phase I)
44.5 months
Incidence of Dose Reductions/Delays (Phase I)
39 months
Overall Response Rate (ORR)
3 years
Clinical Benefit Rate (CBR)
3 years
Disease Control Rate (DCR), Defined as Stable Disease (SD) and Better According to International Myeloma Working Group (IMWG) Uniform Response Criteria (Phase II)
42 days
+7 more secondary outcomes

Study Arms (2)

Arm I (pomalidomide, dexamethasone)

EXPERIMENTAL

Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.

Drug: pomalidomideDrug: dexamethasone

Arm II (pomalidomide, dexamethasone, ixazomib)

EXPERIMENTAL

Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: pomalidomideDrug: ixazomibDrug: dexamethasone

Interventions

pomalidomideDRUG

given PO

Also known as: Pomalyst®

Arm I (pomalidomide, dexamethasone)Arm II (pomalidomide, dexamethasone, ixazomib)

ixazomibDRUG

given PO

Also known as: MLN9708

Arm II (pomalidomide, dexamethasone, ixazomib)

dexamethasoneDRUG

given PO

Arm I (pomalidomide, dexamethasone)Arm II (pomalidomide, dexamethasone, ixazomib)

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

* Histologically confirmed diagnosis of symptomatic multiple myeloma; relapsed disease is myeloma that has previously responded to prior therapy (MR or better) and subsequently progressed * Patient must have measurable disease or non-measurable disease, defined as one or more of the following holding true: * Measurable disease: * Serum M-protein \>= 1.0 g/dL (\>= 0.5 g/dL for IgA or IgM myeloma) and/or * Urine M-protein \>= 200 mg/24 hours and/or * Involved serum free light chain level \>= 10 mg/dL AND an abnormal serum free light chain ratio * For non-measurable disease: * Baseline marrow burden of myeloma of at least 30% * Progression on lenalidomide as part of first line therapy (lenalidomide-refractory disease) \* Lenalidomide-refractory disease is defined as disease progression on or progression within 60 days of the last dose of a lenalidomide-based treatment; patients should have received at least 2 cycles of a lenalidomide-based regimen to be evaluable for refractoriness; examples: 1) progression on lenalidomide maintenance therapy after initial induction +/- consolidation; 2) initial response followed by progression on continuous lenalidomide-dexamethasone +/- elotuzumab or daratumumab * Pomalidomide naive disease * Proteasome inhibitor naive or sensitive disease; proteasome inhibitor sensitive disease is defined as a PR or better to prior proteasome inhibitor-based therapy that is maintained for \>= 60 days from the last dose of the proteasome inhibitor \* A patient who receives induction therapy with lenalidomide, bortezomib and dexamethasone and achieves a PR or better but subsequently progresses on continued lenalidomide or lenalidomide-dexamethasone would be eligible provided the progression occurs 60 days or more after discontinuation of the bortezomib; similarly, ixazomib exposure is allowed provided they meet the definition of proteasome inhibitor sensitive disease * 1 prior line of systemic therapy for multiple myeloma, where a line of therapy for myeloma is defined as 1 or more planned cycles of single agent or combination therapy, as well as a planned series of treatment regimens administered in a sequential manner (e.g. lenalidomide, bortezomib and dexamethasone induction therapy for 4 cycles followed by autologous stem cell transplantation and then lenalidomide maintenance therapy would be considered 1 line of prior therapy); a new line of therapy begins when a planned therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, disease relapse or treatment-related toxicity (e.g. a patient is progressing in the face of lenalidomide maintenance therapy and has bortezomib and dexamethasone added into their regimen); a new line of therapy also begins when a planned treatment-free interval is interrupted by the need to start treatment due to disease relapse/progression (e.g. a patient with relapsed myeloma achieves a partial response after a planned 8 cycles of cyclophosphamide, bortezomib and dexamethasone, enjoys an 8-month period off therapy but then experiences disease progression requiring re-initiation of therapy) * Allogeneic stem cell transplantation is allowed provided the patient is \>= 1 year from transplant at time of registration, is not on immunosuppressive therapy to treat/prevent graft-versus-host disease, has no evidence of active graft versus host disease, and no evidence of active infection * No other chemotherapy or radiation therapy within 14 days prior to registration * No investigational therapy within 14 days prior to registration * No major surgery within 28 days prior to registration * No G-CSF (filgrastim) or GM-CSF (sargramostim) within 7 days of registration or pegfilgrastim within 14 days of registration to meet eligibility criteria * No platelet transfusions within 7 days of registration to meet eligibility criteria; Note: red blood cell transfusions are allowed at any time * A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * Women of childbearing potential: * Must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mlU/ml no more than 14 days prior to registration and must agree to repeat this test within 24 hours of starting pomalidomide * Must either commit to complete abstinence from heterosexual contact or begin TWO acceptable methods of birth control, one highly effective method and one additional effective (barrier) method, AT THE SAME TIME, before starting pomalidomide * Must agree to ongoing pregnancy testing * Must agree to not become pregnant or breast feed a child during treatment on this protocol * Men must practice complete abstinence or agree to use a condom during sexual contact with a female of childbearing potential, even if they have had a successful vasectomy * Note: All participants must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/L * Platelet count \>= 50 x 10\^9/L * Calculated (Calc.) creatinine clearance \>= 30 mL/min; calculated utilizing the Cockcroft-Gault formula or 24-hour urine collection * Total bilirubin \< 1.5 x upper limits of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 x upper limits of normal (ULN) * Note: G-CSF and platelet transfusions cannot be used to increase counts to meet eligibility criteria * Patients cannot have: * Central nerve system involvement * Primary refractory multiple myeloma, where primary refractory multiple myeloma is defined as disease that is nonresponsive - patients who have never achieved a minimal response (MR) or better - with any therapy over the course of their disease; it includes patients who never achieve MR or better in whom there is no significant change in M-protein and no evidence of clinical progression as well as patients who meet criteria for true progressive disease (PD) * Primary or secondary plasma cell leukemia * Light-chain (AL) amyloidosis or polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome * Known active hepatitis C based on: * +hepatitis C virus (HCV) antibody (confirmed) * +HCV RNA * Liver disease with history of positive serology * Note: patients with a prior history of hepatitis C that has been successfully eradicated with antiviral therapy are eligible * Known hepatitis B surface antigen positivity * Previous hypersensitivity to any of the components of the study treatment * Prior history of erythema multiforme with thalidomide or lenalidomide treatment * =\< grade 2 peripheral neuropathy * Adequate cardiac function, defined as: * No electrocardiogram (EKG) evidence of acute ischemia * No EKG evidence of active, clinically significant conduction system abnormalities * No EKG evidence of \> grade 2 (\> 480 ms) corrected QT (QTc) prolongation * Prior to study entry, any EKG abnormality at screening not felt to put the patient at risk has to be documented by the investigator as not medically significant * No uncontrolled angina or severe ventricular arrhythmias * No clinically significant pericardial disease * No history of myocardial infarction within 6 months prior to registration * No class 3 or higher New York Heart Association congestive heart failure * No strong inducers of cytochrome P450 (CYP) 3A4 or CYP1A2 or strong inhibitors of CYP3A4 or CYP1A2 within 14 days prior to registration * Note: Ixazomib is a substrate of CYP3A4 and CYP1A2 * Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following: * No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness * Cluster of differentiation (CD)4+ cells nadirs \> 350/mm\^3 within 28 days prior to registration * Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load \< 50 copies/mm\^3 within 28 days prior to registration * Note: HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4 * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Patients randomized to Arm 1 may opt to switch to the 3-drug regimen following disease progression; these patients must be re-registered to the study and meet the eligibility criteria below * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Patient must have measurable disease or non-measurable disease after progression on pomalidomide + dexamethasone, defined as one or more of the following holding true: \* Measurable disease: * Serum M-protein \>= 0.5 g/dL and/or * Urine M-protein \>= 200 mg/24 hours and/or * Involved serum free light chain level \>= 10 mg/dL AND an abnormal serum free light chain ratio \* For non-measurable disease: * Marrow burden of myeloma of at least 30% * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): * Women of childbearing potential: \*\* Must have a negative serum or urine pregnancy test within 72 hours prior to re-registration \*\* Must either commit to complete abstinence from heterosexual contact or begin TWO acceptable methods of birth control, one highly effective method and one additional effective (barrier) method, AT THE SAME TIME, before starting pomalidomide \*\* Must agree to ongoing pregnancy testing \*\* Must agree to not become pregnant or breast feed a child during treatment on this protocol * Men must practice complete abstinence or agree to use a condom during sexual contact with a female of childbearing potential, even if they have had a successful vasectomy * Note: All participants must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): ECOG performance status 0-2 * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/L * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Platelet count \>= 50 x 10\^9/L * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Calc. creatinine clearance \>= 30 mL/min \* Calculated utilizing the Cockcroft-Gault formula or 24-hour urine collection * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Total bilirubin \< 1.5 x upper limits of normal (ULN) * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): AST and ALT \< 2.5 x upper limits of normal (ULN) * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Note: G-CSF and platelet transfusions cannot be used to increase counts to meet eligibility criteria * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): =\< grade 2 peripheral neuropathy * RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): No strong inducers of cytochrome P450 (CYP) 3A4 or CYP1A2 or strong inhibitors of CYP3A4 or CYP1A2 \* Note: Ixazomib is a substrate of CYP3A4 and CYP1A2

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Alliance for Clinical Trials in Oncologylead
National Cancer Institute (NCI)collaborator
Celgene Corporationcollaborator
Millennium Pharmaceuticals, Inc.collaborator

Study Sites (336)

Anchorage Associates in Radiation Medicine

Anchorage, Alaska, 98508, United States

Location

Anchorage Radiation Therapy Center

Anchorage, Alaska, 99504, United States

Location

Alaska Breast Care and Surgery LLC